Old and new oral anticoagulants: Food, herbal medicines and drug interactions.

[1]  A. Quyyumi,et al.  HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review , 2016, HIV medicine.

[2]  E. Tremoli,et al.  Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. , 2015, Thrombosis research.

[3]  J. Peral-Aguirregoitia,et al.  Probable interaction between acenocoumarol and levofloxacin: a case series , 2015, Journal of clinical pharmacy and therapeutics.

[4]  J. Beyer-Westendorf,et al.  Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.

[5]  T. Schalekamp,et al.  Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon , 2015, European Journal of Clinical Pharmacology.

[6]  A. Di Minno,et al.  Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. , 2015, Blood reviews.

[7]  P. Babu,et al.  Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[8]  R. V. van Breemen,et al.  Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements , 2015, Drug Metabolism and Disposition.

[9]  B. McEwen,et al.  The Influence of Herbal Medicine on Platelet Function and Coagulation: A Narrative Review , 2015, Seminars in Thrombosis & Hemostasis.

[10]  J. Beyer-Westendorf,et al.  Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.

[11]  T. Kondo,et al.  Effect of lyophilized grapefruit juice on P-glycoprotein-mediated drug transport in-vitro and in-vivo , 2015, Drug development and industrial pharmacy.

[12]  Shu-Feng Zhou,et al.  Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies , 2015, Drug design, development and therapy.

[13]  J. Finsterer,et al.  Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban , 2015, Herz.

[14]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[15]  G. Zaccara,et al.  Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. , 2014, Epileptic disorders : international epilepsy journal with videotape.

[16]  S. Harder.  Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism , 2014, Thrombosis Journal.

[17]  A. Shenker,et al.  Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. , 2014, British journal of clinical pharmacology.

[18]  Ye Zhang,et al.  Evaluation of genipin on human cytochrome P450 isoenzymes and P-glycoprotein in vitro. , 2014, Fitoterapia.

[19]  A. Camm,et al.  Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor , 2014, Drugs.

[20]  G. Lippi,et al.  Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring? , 2014, Seminars in Thrombosis & Hemostasis.

[21]  W. Lijfering,et al.  Metformin use decreases the anticoagulant effect of phenprocoumon , 2014, Journal of thrombosis and haemostasis : JTH.

[22]  H. Ghofrani,et al.  Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. , 2014, Pulmonary pharmacology & therapeutics.

[23]  E. Russo,et al.  Hypericum perforatum: Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug–Drug Interactions , 2014, Phytotherapy research : PTR.

[24]  A. Bogacz,et al.  The influence of soybean extract on the expression level of selected drug transporters, transcription factors and cytochrome P450 genes encoding phase I drug-metabolizing enzymes. , 2014, Ginekologia polska.

[25]  P. Hariharan,et al.  Potential modulation on P-glycoprotein and CYP3A by soymilk and miso: in vivo and ex-vivo studies. , 2014, Food chemistry.

[26]  Z. Zuo,et al.  Updates on the Clinical Evidenced Herb-Warfarin Interactions , 2014, Evidence-based complementary and alternative medicine : eCAM.

[27]  B. Norrving,et al.  Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk , 2014, Vascular health and risk management.

[28]  M. Ackman,et al.  Drug Interactions Between Antiplatelet or Novel Oral Anticoagulant Medications and Antiretroviral Medications , 2014, The Annals of pharmacotherapy.

[29]  J. Hirsh,et al.  New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions , 2014, Thrombosis and Haemostasis.

[30]  B. Bajorek,et al.  New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations , 2014, American Journal of Cardiovascular Drugs.

[31]  D. Colombo,et al.  Cyclosporine and Herbal Supplement Interactions , 2014, Journal of toxicology.

[32]  Xue-jia Zhai,et al.  Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[33]  W. Klauser,et al.  Practical management of new oral anticoagulants after total hip or total knee arthroplasty , 2013, MUSCULOSKELETAL SURGERY.

[34]  M. Si,et al.  Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P‐glycoprotein , 2013, Chinese medical journal.

[35]  A. Di Minno,et al.  Clinical Judgment When Using Coagulation Tests during Direct Oral Anticoagulant Treatment: A Concise Review , 2013, Seminars in Thrombosis and Hemostasis.

[36]  W. Mueck,et al.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban , 2013, Clinical Pharmacokinetics.

[37]  S. Schiffman,et al.  Sucralose, A Synthetic Organochlorine Sweetener: Overview of Biological Issues , 2013, Journal of toxicology and environmental health. Part B, Critical reviews.

[38]  I. Martinelli,et al.  Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. , 2013, Thrombosis research.

[39]  M. Samama,et al.  The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor , 2013, Journal of cardiovascular pharmacology.

[40]  A. Halabi,et al.  Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2013, British journal of clinical pharmacology.

[41]  N. Srinivas.  Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. , 2013, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[42]  F. Lee,et al.  Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor , 2013, American Journal of Cardiovascular Drugs.

[43]  M. Moia,et al.  Laboratory tests during direct oral anticoagulant treatment , 2013, Internal and Emergency Medicine.

[44]  A. Iorio,et al.  Prophylaxis of venous thromboembolism in elderly patients with multimorbidity , 2013, Internal and Emergency Medicine.

[45]  D. DeMets,et al.  Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[46]  K. Cabral,et al.  Pharmacology of the new target-specific oral anticoagulants , 2013, Journal of Thrombosis and Thrombolysis.

[47]  V. Rollason,et al.  Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. , 2013, Pharmacogenomics.

[48]  S. Harder,et al.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations , 2013, European Journal of Clinical Pharmacology.

[49]  J. Mendell,et al.  A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. , 2013, British journal of clinical pharmacology.

[50]  S. Härtter,et al.  Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. , 2013, British journal of clinical pharmacology.

[51]  J. Morales-Molina,et al.  Interaction between ciclopirox and acenocoumarol , 2013, European Journal of Clinical Pharmacology.

[52]  M. Barclay,et al.  Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring , 2013, British journal of clinical pharmacology.

[53]  F. Scaglione.  New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists , 2013, Clinical Pharmacokinetics.

[54]  Spencer E. Harpe,et al.  Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic. , 2012, The American journal of geriatric pharmacotherapy.

[55]  H. Masumoto,et al.  Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans , 2012, Drug Metabolism and Disposition.

[56]  J. Seiffge,et al.  Neue Antikoagulanzien - Stellenwert inder Sekundärprävention nach Hirnschlag , 2012 .

[57]  Yan-Ling He.  Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin , 2012, Clinical Pharmacokinetics.

[58]  A. Shimony,et al.  Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. , 2012, The American journal of cardiology.

[59]  C. Frost,et al.  Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects , 2012, British journal of clinical pharmacology.

[60]  Su Jianning,et al.  The effects of notoginsenoside R₁ on the intestinal absorption of geniposide by the everted rat gut sac model. , 2012, Journal of ethnopharmacology.

[61]  J. Morales-Molina,et al.  Interaction between amorolfine and acenocoumarol , 2012, European Journal of Clinical Pharmacology.

[62]  Theresa J. Schindel,et al.  Evaluation of a multi staged professional development course for practising pharmacists in anticoagulation management , 2012, The International journal of pharmacy practice.

[63]  D. Kubitza,et al.  Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study , 2012, Pharmaceuticals.

[64]  M. Oertle.  Frequency and nature of drug-drug interactions in a Swiss primary and secondary acute care hospital. , 2012, Swiss medical weekly.

[65]  Mark Crowther,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[66]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[67]  E. Hylek,et al.  Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. , 2011, Blood.

[68]  Y. Sawada,et al.  Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model , 2011, Journal of clinical pharmacy and therapeutics.

[69]  R. Rathbun,et al.  Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management , 2011, Pharmaceutics.

[70]  S. Spinler,et al.  The Role of Apixaban for Venous and Arterial Thromboembolic Disease , 2011, The Annals of pharmacotherapy.

[71]  J. Juřica,et al.  The effect of St John's wort (hypericum perforatum) on cytochrome p450 1a2 activity in perfused rat liver. , 2011, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[72]  J. Morales-Molina,et al.  Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far , 2011, Hematology reports.

[73]  U. Buetehorn,et al.  In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban , 2011, Journal of Pharmacology and Experimental Therapeutics.

[74]  C. Lau,et al.  Effect of Herbal Consumption on Time in Therapeutic Range of Warfarin Therapy in Patients With Atrial Fibrillation , 2011, Journal of cardiovascular pharmacology.

[75]  A. Hofman,et al.  Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment , 2011, British journal of haematology.

[76]  S. Behr,et al.  Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database , 2011, European Journal of Clinical Pharmacology.

[77]  G. Hamann,et al.  Warfarin-Cranberry Juice Interaction , 2011, The Annals of pharmacotherapy.

[78]  E. Nutescu,et al.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update , 2011, Journal of Thrombosis and Thrombolysis.

[79]  R. Hamers,et al.  Interaction between Antiretroviral Drugs and Acenocoumarol , 2011, Antiviral therapy.

[80]  A. Vannacci,et al.  Interactions between Natural Health Products and Oral Anticoagulants: Spontaneous Reports in the Italian Surveillance System of Natural Health Products , 2011, Evidence-based complementary and alternative medicine : eCAM.

[81]  C. Andrade,et al.  Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. , 2010, The Journal of clinical psychiatry.

[82]  A. Clemens,et al.  Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[83]  E. Antman,et al.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.

[84]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[85]  Fredrik Folke,et al.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.

[86]  G. Garrido,et al.  In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. , 2010, Chemico-biological interactions.

[87]  H. Halkin,et al.  Warfarin and vitamin K intake in the era of pharmacogenetics. , 2010, British journal of clinical pharmacology.

[88]  Sepehr Shakib,et al.  Warfarin--indications, risks and drug interactions. , 2010, Australian Family Physician.

[89]  M. Ford,et al.  Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. , 2010, British journal of clinical pharmacology.

[90]  C. Adiguzel,et al.  Drug and dietary interactions of the new and emerging oral anticoagulants , 2010, International journal of clinical practice.

[91]  P. Dorian.  Clinical Pharmacology of Dronedarone: Implications for the Therapy of Atrial Fibrillation , 2010, Journal of cardiovascular pharmacology and therapeutics.

[92]  A. Laupacis,et al.  Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. , 2010, Archives of internal medicine.

[93]  Hyo-Kyung Han,et al.  Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. , 2010, Journal of food science.

[94]  C. di Ilio,et al.  Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. , 2010, Journal of biological regulators and homeostatic agents.

[95]  W. Humphreys,et al.  In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies , 2010, Drug Metabolism and Disposition.

[96]  R. Rathbun,et al.  Drug interactions with antiretrovirals and warfarin , 2010, Expert opinion on drug safety.

[97]  M. Wink,et al.  Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. , 2010, European journal of pharmacology.

[98]  C. Faria,et al.  Probable Warfarin Interaction with Menthol Cough Drops , 2010, Pharmacotherapy.

[99]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[100]  J. Morales-Molina,et al.  Possible Interaction Between Topical Terbinafine and Acenocoumarol , 2009, The Annals of pharmacotherapy.

[101]  S. Shord,et al.  Drug—Botanical Interactions: A Review of the Laboratory, Animal, and Human Data for 8 Common Botanicals , 2009, Integrative cancer therapies.

[102]  D. Greenblatt,et al.  The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Double‐Blind Trial , 2009, Journal of clinical pharmacology.

[103]  Deepak L. Bhatt,et al.  Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.

[104]  J. Sandoval,et al.  Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension , 2009, European journal of clinical investigation.

[105]  C. Weinz,et al.  Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans , 2009, Drug Metabolism and Disposition.

[106]  Wei Zhang,et al.  Effects of Ginkgo biloba Extract Ingestion on the Pharmacokinetics of Talinolol in Healthy Chinese Volunteers , 2009, The Annals of pharmacotherapy.

[107]  M. Fischereder,et al.  Effects of Dietary Factors on Drug Transport and Metabolism: The Impact on Dosage Guidelines in Transplant Patients , 2009, Clinical pharmacology and therapeutics.

[108]  S. Laporte,et al.  Investigation of PK–PD drug–drug interaction between acenocoumarol and amoxicillin plus clavulanic acid , 2009, Fundamental & clinical pharmacology.

[109]  R. Rathbun,et al.  Warfarin–Antiretroviral Interactions , 2009, The Annals of pharmacotherapy.

[110]  J. Ansell,et al.  Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict , 2008 .

[111]  S. Pegler,et al.  Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin , 2008, The journal of the Royal Society for the Promotion of Health.

[112]  S. Hennessy,et al.  Warfarin With Fluoroquinolones, Sulfonamides, or Azole Antifungals: Interactions and the Risk of Hospitalization for Gastrointestinal Bleeding , 2008, Clinical pharmacology and therapeutics.

[113]  C. Lions,et al.  Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. , 2008, The American journal of geriatric pharmacotherapy.

[114]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[115]  L. Jacobs.  Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. , 2008, Cardiology clinics.

[116]  K. P. Mathews,et al.  Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. , 2008, The Journal of the Association of Physicians of India.

[117]  T. Self,et al.  Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. , 2008, The American journal of geriatric pharmacotherapy.

[118]  S. Burchiel,et al.  Risks and benefits of commonly used herbal medicines in Mexico. , 2008, Toxicology and applied pharmacology.

[119]  T. Ebner,et al.  The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans , 2008, Drug Metabolism and Disposition.

[120]  P. Souverein,et al.  Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. , 2008, Archives of internal medicine.

[121]  Larisa H Cavallari,et al.  Factors influencing warfarin dose requirements in African-Americans. , 2007, Pharmacogenomics.

[122]  Bonnie K. Lind,et al.  Potential Interactions Between Complementary/Alternative Products and Conventional Medicines in a Medicare Population , 2007, The Annals of pharmacotherapy.

[123]  C. Washington,et al.  Ciprofloxacin Prolonged‐Release Tablets Do Not Affect Warfarin Pharmacokinetics and Pharmacodynamics , 2007, Journal of clinical pharmacology.

[124]  Karissa Y. Kim,et al.  Interaction Between Warfarin and Nafcillin: Case Report and Review of the Literature , 2007, Pharmacotherapy.

[125]  D. Jakab,et al.  Food drug interactions , 2007 .

[126]  Zhenya Shen,et al.  Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients , 2007, European Journal of Clinical Pharmacology.

[127]  E. Molden,et al.  Probable Warfarin–Simvastatin Interaction , 2007, The Annals of pharmacotherapy.

[128]  S. Hasan.  Interaction of Doxycycline and Warfarin: An Enhanced Anticoagulant Effect , 2007, Cornea.

[129]  W. Mueck,et al.  Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. , 2007, British journal of clinical pharmacology.

[130]  T. Rundlöf,et al.  Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy , 2007, European Journal of Clinical Pharmacology.

[131]  A. de Boer,et al.  Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction , 2007, European Journal of Clinical Pharmacology.

[132]  T. Cheng.  Green tea may inhibit warfarin. , 2007, International journal of cardiology.

[133]  N. Seeram,et al.  Cranberry does not affect prothrombin time in male subjects on warfarin. , 2006, Journal of the American Dietetic Association.

[134]  R. Ryono,et al.  Anticoagulation‐Related Outcomes in Patients Receiving Warfarin After Starting Levofloxacin or Gatifloxacin , 2006, Pharmacotherapy.

[135]  J. Hallas,et al.  Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study , 2006, BMJ : British Medical Journal.

[136]  W. Mueck,et al.  Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin , 2006, Journal of clinical pharmacology.

[137]  A. Laupacis,et al.  Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. , 2006, The American journal of medicine.

[138]  E. Nutescu,et al.  Warfarin and its interactions with foods, herbs and other dietary supplements , 2006, Expert opinion on drug safety.

[139]  B. Trock,et al.  Meta-analysis of soy intake and breast cancer risk. , 2006, Journal of the National Cancer Institute.

[140]  H. Stuppner,et al.  Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. , 2006, Life sciences.

[141]  D. Greenblatt,et al.  Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies , 2006, Clinical pharmacology and therapeutics.

[142]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[143]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[144]  B. Eriksson,et al.  Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement , 2005, Journal of clinical pharmacology.

[145]  R. Day,et al.  Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. , 2005, British journal of clinical pharmacology.

[146]  D. Greenblatt,et al.  Interaction of Warfarin With Drugs, Natural Substances, and Foods , 2005, Journal of clinical pharmacology.

[147]  D. L. Shaw,et al.  Possible Warfarin Interaction with Menthol Cough Drops , 2005, The Annals of pharmacotherapy.

[148]  E. Ernst,et al.  Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. , 2005, International journal of cardiology.

[149]  M. Shearer,et al.  Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. , 2004, Blood.

[150]  L. Dey,et al.  American ginseng reduces warfarin’s effect in healthy patients: A randomized, controlled trial☆ , 2004 .

[151]  D. Greenblatt,et al.  Inhibition of human cytochromes P450 by components of Ginkgo biloba , 2004, The Journal of pharmacy and pharmacology.

[152]  E. Ernst,et al.  Co-ingestion of herbal medicines and warfarin. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[153]  R. Day,et al.  Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. , 2004, British journal of clinical pharmacology.

[154]  H. Echizen,et al.  CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences , 2004, Clinical pharmacology and therapeutics.

[155]  M. Moia,et al.  CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy , 2004, Clinical pharmacology and therapeutics.

[156]  F. Kamali,et al.  Dietary vitamin K influences intra‐individual variability in anticoagulant response to warfarin , 2004, British journal of haematology.

[157]  J. Goldstein,et al.  Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[158]  Miranda R Andrus,et al.  Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature , 2004, Pharmacotherapy.

[159]  M. Barry.  Rosuvastatin — warfarin drug interaction , 2004, The Lancet.

[160]  M. Pirmohamed,et al.  Possible interaction between warfarin and cranberry juice , 2003, BMJ : British Medical Journal.

[161]  S. Booth,et al.  Vitamin K content of nuts and fruits in the US diet. , 2003, Journal of the American Dietetic Association.

[162]  A. Abdelhafiz,et al.  Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. , 2003, The American journal of geriatric pharmacotherapy.

[163]  N. Wood,et al.  Voriconazole potentiates warfarin-induced prothrombin time prolongation. , 2003, British journal of clinical pharmacology.

[164]  A. D. Rodrigues,et al.  Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[165]  D. Nelson,et al.  Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. , 2003, Gastrointestinal endoscopy.

[166]  M. Rosado.  Thrombosis of a Prosthetic Aortic Valve Disclosing a Hazardous Interaction between Warfarin and a Commercial Ginseng Product , 2003, Cardiology.

[167]  L. Davydov,et al.  Warfarin and Amoxicillin/Clavulanate Drug Interaction , 2003, The Annals of pharmacotherapy.

[168]  Min Huang,et al.  Interactions of Herbs with Cytochrome P450 , 2003, Drug metabolism reviews.

[169]  E. Ellerbeck,et al.  The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation , 2002, Pharmacoepidemiology and drug safety.

[170]  Josie A. Cambria-Kiely.  Effect of Soy Milk on Warfarin Efficacy , 2002, The Annals of pharmacotherapy.

[171]  K. Winther,et al.  Effect of Coenzyme Q10 and Ginkgo biloba on Warfarin Dosage in Stable, Long-term Warfarin Treated Outpatients. A Randomised, Double Blind, Placebo-crossover Trial , 2002, Thrombosis and Haemostasis.

[172]  Giselle C Rivera-Miranda,et al.  Interaction between Warfarin and Mango Fruit , 2002, The Annals of Pharmacotherapy.

[173]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[174]  C. Ioannides.  Pharmacokinetic interactions between herbal remedies and medicinal drugs , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[175]  D. Bartolozzi,et al.  Need for increased dose of warfarin in HIV patients taking nevirapine. , 2001, AIDS.

[176]  J. Stangier,et al.  Steady‐State Pharmacodynamics and Pharmacokinetics of Warfarin in the Presence and Absence of Telmisartan in Healthy Male Volunteers , 2000, Journal of clinical pharmacology.

[177]  T. Trujillo,et al.  Antiarrhythmic Agents , 2000, Drug safety.

[178]  F. Gonzalez,et al.  Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[179]  E. Seifritz,et al.  Inhibition of phenprocoumon anticoagulation by carbamazepine , 2000, European Neuropsychopharmacology.

[180]  A. Iorio,et al.  Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity , 2000, Thrombosis and Haemostasis.

[181]  D. Thirion,et al.  Potentiation of Warfarin's Hypoprothrombinemic Effect with Miconazole Vaginal Suppositories , 2000, Pharmacotherapy.

[182]  M. Harkey,et al.  Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. , 1999, Life sciences.

[183]  D. Foster,et al.  Potential Interaction Between Azithromycin and Warfarin , 1999, Pharmacotherapy.

[184]  Y. Takiguchi,et al.  Acute Effects of Griseofulvin on the Pharmacokinetics and Pharmacodynamics of Warfarin in Rats , 1999, The Journal of international medical research.

[185]  M. González-Escribano,et al.  CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. , 1999, Tissue antigens.

[186]  Jennifer C. Lin,et al.  The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin , 1999, Journal of clinical pharmacology.

[187]  J. Rowin,et al.  Association of Ginkgo biloba with intracerebral hemorrhage , 1998, Neurology.

[188]  M. Darlington,et al.  Hypoprothrombinemia during Concomitant Therapy with Warfarin and Saquinavir , 1997, The Annals of pharmacotherapy.

[189]  A. Morreale,et al.  Probable interaction between warfarin and ginseng. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[190]  P. Thürmann,et al.  Clinically Important Drug Interactions with Anticoagulants , 1996, Clinical pharmacokinetics.

[191]  R. Meyboom,et al.  [Possible potentiation of phenprocoumon by clarithromycin and roxithromycin]. , 1996, Nederlands tijdschrift voor geneeskunde.

[192]  J. Hirsh,et al.  Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.

[193]  K. Gericke.  Possible Interaction Between Warfarin and Fluconazole , 1993, Pharmacotherapy.

[194]  T. Seaton,et al.  Possible Potentiation of Warfarin by Fluconazole , 1990, DICP : the annals of pharmacotherapy.

[195]  P. Bousquet.  [Pharmacology of neurotransmitters. Current data on the central regulation of blood pressure]. , 1990, Therapie.

[196]  K. Chung,et al.  EFFECT OF A GINKGOLIDE MIXTURE (BN 52063) IN ANTAGONISING SKIN AND PLATELET RESPONSES TO PLATELET ACTIVATING FACTOR IN MAN , 1987, The Lancet.

[197]  J. Bouma,et al.  CERVICAL CARCINOMA IN YOUNGER PATIENTS , 1983, The Lancet.

[198]  A. Bint,et al.  Adverse Antibiotic Drug Interactions , 1980, Drugs.

[199]  V. Escudero-Vilaplana,et al.  Increased INR after gefitinib and acenocoumarol co-administration. , 2014, European review for medical and pharmacological sciences.

[200]  C. Smorenburg,et al.  [Increased INR from concomitant use of acenocoumarol and capecitabine]. , 2012, Nederlands tijdschrift voor geneeskunde.

[201]  K. Dalhoff,et al.  Food-Drug Interactions , 2012, Drugs.

[202]  K. Nedeltchev,et al.  [The new anticoagulants - their role in secondary prevention of thromboembolism after stroke]. , 2012, Therapeutische Umschau. Revue therapeutique.

[203]  G. Lip,et al.  New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes , 2012 .

[204]  Angelo A. Izzo,et al.  Interactions Between Herbal Medicines and Prescribed Drugs , 2012, Drugs.

[205]  Stacy L. Haber,et al.  Cranberry and warfarin interaction: a case report and review of the literature. , 2012, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[206]  W. Ageno,et al.  Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Oral Anticoagulant Therapy : Antithrombotic , 2012 .

[207]  W. Ageno,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis , 2012 .

[208]  J. Stockman.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study , 2011 .

[209]  Gordon H. Guyatt,et al.  Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 2011 .

[210]  B. Eriksson,et al.  Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development , 2009, Clinical pharmacokinetics.

[211]  E. Leiva Badosa,et al.  Retrospective assessment of potential interaction between levofloxacin and warfarin , 2009, Pharmacy world & science : PWS.

[212]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[213]  U. Fuhr,et al.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization. , 2008, Clinical pharmacokinetics.

[214]  G. di Perri,et al.  Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[215]  U. Fuhr,et al.  Pharmacogenetics of Oral Anticoagulants , 2008, Clinical pharmacokinetics.

[216]  D. Wei,et al.  Reversal of cancer multidrug resistance by green tea polyphenols , 2004, The Journal of pharmacy and pharmacology.

[217]  Lian-qingGUO,et al.  Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines , 2004 .

[218]  Ginseng Reduces the Effect of Warfarin in a Study of Healthy Volunteers , 2004, Annals of Internal Medicine.

[219]  J. Arnason,et al.  In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. , 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[220]  S. Booth,et al.  Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). , 1995, Journal of the American Dietetic Association.

[221]  P. Beaune,et al.  Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. , 1993, Molecular pharmacology.

[222]  P. Bousquet.  Pharmacologie des neuromédiateurs : données actuelles sur la régulation central de la pression artérielle , 1990 .